Showing 15 posts of 22 posts found.


Sanofi and Regeneron’s Praluent approved in Europe to reduce CV risk

March 18, 2019
Research and Development, Sales and Marketing Regeneron, Sanofi, cardiovascular, heart, praluent

Sanofi and Regeneron’s Praluent (alirocumab) has been awarded approval by the European Commission, it has emerged, as a therapy to …


Human heart patch could repair dead tissue following heart attack

November 29, 2017
Research and Development Duke University, heart, heart patch, human heart, pharma

A team of researchers and biomedical engineers at Duke University in North Carolina, US, have revealed that they have developed …


Where will the next cardiovascular breakthrough come from?

August 17, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing British Heart Foundation, cardiovascular disease, heart, heart disease, pharma, pharmaceutical

British Heart Foundation’s Jennifer Mitchell, Research Communications Officer, explains the work they are doing to find the next breakthrough treatment …


Heart failure mortality rates fall across England and Wales, national audit finds

August 11, 2017
Medical Communications, Research and Development cardiovascular, heart, heart disease, life sciences, pharma, pharmaceutical

Great news in the cardiovascular space as results from the National Heart Failure Audit indicate that better treatment has led …


Heart scan offers possibility of non-invasive diagnosis

July 13, 2017
Medical Communications, Research and Development biotech, cardiovascular, drugs, heart, heart scan, pharma, pharmaceutical

Scientists from the University of Oxford have developed a heart scan that can identify inflammation around arteries that can suggest …

Amgen image

FDA approves Amgen’s heart failure drug

April 16, 2015
Sales and Marketing Amgen, Corlanor, FDA, NICE, Vectibix, heart, ivabradine

Amgen has earned sign-off from the FDA for Corlanor as a treatment for people with worsening heart failure symptoms. Corlanor …

Actos image

Takeda offers $2.2 billion to resolve Actos damages claims

April 1, 2015
Sales and Marketing Actos, Cancer, Takeda, bladder, diabetes, heart, pioglitazone

Takeda has attempted to settle its hefty damages bill over claims it was hiding cancer risks in its diabetes drug …


FDA approves Eisai thyroid drug, fast-tracks Novartis heart pill

February 16, 2015
Sales and Marketing Eisai, FDA, LCZ696, Lenvima, Novartis, heart, lenvatinib, thyroid

The FDA has approved Eisai’s thyroid cancer drug Lenvima and also granted Novartis heart pill LCZ696 a priority review.  Lenvima …

Nexium image

Teva’s Nexium copycat approved in US

January 27, 2015
Manufacturing and Production, Sales and Marketing AstraZeneca, Teva, esomeprazole, gerd, heart, nsaids

Teva has won approval for its copycat form of AstraZeneca’s big-selling heatburn drug Nexium, making it the first generic version …

Sanofi image

Sanofi and Regeneron post positive alirocumab results

January 9, 2015
Sales and Marketing Regeneron, Sanofi, cholesterol, heart, statin, statins

The latest trials of the potentially blockbuster new heart drug alirocumab show it lowers cholesterol in people at moderate and …

NHS image

NHS plans bashed over cancer and heart disease

December 24, 2014
Research and Development, Sales and Marketing Cancer, England, NHS, Simon Stevens, funding, heart

Hundreds of healthcare experts have signed an open letter to NHS chief executive Simon Stevens calling for him to scrap …

Brilinta image

Mixed results for AZ’s troubled Brilinta

September 3, 2014
Sales and Marketing AstraZeneca, Brilinta, EMA, PCI, atlantic, heart, stent

The latest trial for AstraZeneca’s heart drug Brilinta (ticagrelor) has failed to meet expected results but suggests more flexible applications …

Novartis heart drug sees stellar results

September 1, 2014
Sales and Marketing Diovan, LCZ696, Novartis, failure, heart, valsartan

Novartis’ new heart pill has produced stellar results in helping patients with heart failure live longer, making it the first …

novartis image

Novartis faces data fraud charges in Japan

July 3, 2014
Medical Communications, Sales and Marketing Diovan, Japan, Novartis, data, fraud, heart, valsartan

Novartis is facing criminal charges in Japan over the alleged falsifying of data for its once big-selling heart drug Diovan. …

GSK image

More late-stage anguish for GSK heart drug

May 14, 2014
Research and Development, Sales and Marketing GSK, Patrick Vallance, darapladib, heart

GlaxoSmithKline’s experimental heart drug darapladib has failed to meet its primary endpoint in a Phase III trial for the second …

Latest content